CME MULTIMEDIA ACTIVITIES
March 2011
Heparin Induced Thrombocytopenia Redux: Recognition, Treatment, and Prevention
Faculty: E. Magnus Ohman, MD, John L. Francis, PhD, Alan S. Multz, MD, and Thomas L. Ortel, MD, PhD
This series of three CME–accredited Web casts that, as an ensemble, constitute a curriculum on understanding how best to prevent and treat heparin-associated thrombocytopenia.
Commercial Support: Canyon Pharmaceuticals
Review and Sponsorship: This multimedia activity was peer reviewed by The Journal of Critical Care, and The American Journal of Cardiology.
July 2010
CME Preventing Stroke in Atrial Fibrillation: Bridging the Treatment Gap
Faculty: Joseph S. Alpert, MD, Elaine M. Hylek, MD, MPH, Stephen E. Kimmel, MD, MSCE, and Gregory Y. H. Lip, MD
Under the auspices of the International Cardiology Forum, this series of four Web casts will explore management of atrial fibrillation in all its dimensions, from maximizing net clinical benefit in stroke prevention to different approaches to addressing the underlying arrhythmia. In aggregate, these Web casts are intended to serve as a curriculum on this dysrhythmia. These Web casts will consider the latest data on new therapies or strategies, integrating these data into the large body of evidence that has accrued over the past several decades and upon which current treatment guidelines are based.
Commercial Support: Ortho-McNeil Inc, Division of Ortho–McNeil–Janssen Pharmaceuticals, Inc., administered by Ortho–McNeil Janssen Scientific Affairs, LLC.
Review and Sponsorship: This multimedia activity was peer reviewed by The American Journal of Medicine, The American Heart Journal, and The American Journal of Cardiology.
July 2010
Mechanisms and Consequences of Cardiac Ischemia/Reperfusion Injury: Insights and Evidence to Improve Outcomes
Presenters: Roberta A. Gottlieb, MD, Robert M. Mentzer, Jr., MD, and Frank W. Sellke, MD
Cardiologists and cardiac surgeons have long understood the need for cardioprotection to preserve the viability of myocardium during ischemia and reperfusion and research has shed much light on the mechanisms of cell injury and cell death in both ischemia and the reperfusion-associated pathologies. Inadequate myocardial protection and ischemia/reperfusion injury are major problems associated with CABG surgery making the need for cardioprotection necessary and urgent. It is the aim of this case-based, interactive CME activity to provide clinicians with an understanding of the magnitude of ischemia/reperfusion injury and its consequences, the newest information on the various pathways and mechanisms of ischemia/reperfusion injury, and an overview of the ongoing research into cardioprotective options.
Commercial Support: Merck
Review and Sponsorship: This multimedia activity was peer reviewed by The American Journal of Cardiology and The Journal of Thoracic and Cardiovascular Surgery and jointly sponsored by Purdue University College of Pharmacy and Health Education Alliance, Inc.
June 2010
Antiplatelet Therapy in ACS and PCI: Practical Strategies to Improve Outcomes
Presenters: Dominick J. Angiolillo, MD, PhD, FACC, Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, Gilles Montalescot, MD, PhD, and Stephen D. Wiviott, MD, FACC
Clinical practice in the field of antiplatelet therapy in acute coronary syndrome (ACS) is evolving with the development and approval of new therapeutic options. At the same time, recommended practice guidelines will also change. As data rapidly becomes available, it is critical that clinicians become familiar with new compounds and evaluate them in the context of risk stratification, practice guidelines, and individual patient profiles. It is the aim of this program to review the latest clinical information on both new and existing therapies so that patient outcomes can be optimized.
Commercial Support: Daiichi Sankyo, Inc. and Lilly USA, LLC
Review and Sponsorship: This multimedia activity was peer reviewed by The American Journal of Cardiology and jointly sponsored by Purdue University School of Pharmacy and Health Education Alliance, Inc.
February 2010
Antiplatelet Therapy in ACS: Applying New Science to Clinical Decisions
Presenters: Richard C. Becker, MD, C. Michael Gibson, MS, MD, FACC, Lisa K. Jennings, PhD, FAHA, FESC, and David A. Morrow, MD, MPH
Given the number of novel antiplatelet therapies for Acute Coronary Syndrome (ACS) that are in development, and the rapid pace at which new information becomes available, it is critical that clinicians stay up to date on the latest evidence and evaluate compounds in the context of existing standards of care. It is the aim of this interactive, case-based CME activity to review new understandings of platelet physiology and risk stratification, and to provide information on the latest clinical evidence for available and emerging therapies so that clinicians can continue to improve the management and treatment of ACS using antiplatelet therapy.
Commercial Support: Merck
Review and Sponsorship: This multimedia activity was peer reviewed by The American Journal of Cardiology and jointly sponsored by Purdue University School of Pharmacy and Health Education Alliance, Inc.
